DIHEXA

Cognitive EnhancementResearch Only

Laboratory results are striking, but human evidence is practically nonexistent. The potency claims come from cell culture and animal studies that don't always translate to real-world effects.

Primarily studied by Alzheimer's disease researchers and neuroscientists investigating synaptic plasticity mechanisms.

FDA Status

Banned from Compounding

Since Mar 2024

Evidence

Limited data

Studies

9 total, 2 human

What is DIHEXA?

Originally developed as a derivative of angiotensin IV, this small peptide has attracted attention from neuroscience researchers for its unusually high potency in laboratory cognitive enhancement studies. Alzheimer's disease researchers have been particularly interested in its ability to stimulate new synaptic connections in brain tissue. The compound shows activity levels thousands of times higher than brain-derived neurotrophic factor in certain laboratory assays.

The peptide works by hijacking the hepatocyte growth factor receptor system, essentially amplifying signals that tell neurons to grow new connections and survive under stress. When it binds to these receptors, it triggers a cascade of cellular events through the HGF/c-Met pathway that promotes both the formation of new synapses and the survival of existing neurons. Think of it as turning up the volume on the brain's natural growth and repair mechanisms.

What the Research Shows

Nine total studies identified, with only two involving human subjects and no randomized controlled trials completed.

Of 9 total studies identified, only 4 involved human subjects and none were randomized controlled trials. Available evidence suggests DIHEXA may activate HGF/c-Met receptor pathways associated with memory and synaptic formation in Alzheimer's disease models, though clinical efficacy in humans remains unestablished due to the absence of RCT data.